CA-CALDERA-MEDICAL
Caldera Medical, a global leader in women’s pelvic health, is proud to announce its sponsorship of the Cynisca Cycling team. This partnership reflects Caldera Medical’s unwavering commitment to advancing women’s health and empowerment through sports and community engagement.
Cynisca Cycling, an elite women's professional cycling team, is dedicated to elevating female athletes and promoting gender equality in sports. The collaboration with Caldera Medical, renowned for its humanitarian efforts in women's health, is poised to drive significant impact in both the sporting and healthcare arenas.
“We’re extremely pleased to share this new development between our team and Caldera Medical,” commented Robin Farina, Cynisca operations and performance director. “Just like Cynisca, Caldera has made a commitment to advancing women. Through our collaboration, we’ll continue to support women both on and off the bike.”
“Our sponsorship of Cynisca Cycling aligns perfectly with Caldera Medical’s mission to enhance the quality of life for women around the world,” said Bryon Merade, CEO of Caldera Medical. “We believe that empowering women in sports contributes to their overall well-being and health. By supporting Cynisca Cycling, we aim to underscore the importance of physical activity, resilience, and community for women's health.”
Caldera Medical’s involvement with Cynisca Cycling will include:
Health and Wellness Workshops: Organizing workshops focused on pelvic health, mental wellness, and overall physical health for the athletes and their communities.
Awareness Campaigns: Launching joint campaigns to educate the public about women's health issues and the importance of regular check-ups and active lifestyles.
Community Engagement: Participating in community events and activities that promote women's health and empowerment.
This sponsorship represents a significant step in Caldera Medical’s broader mission to address and improve women's health globally. The partnership with Cynisca Cycling will provide a dynamic platform to promote health, fitness, and empowerment among women, resonating with Caldera’s core values of compassion, excellence, and innovation.
About Caldera Medical
Caldera Medical is a medical device company solely focused on women’s health with a commitment to our mission of “Improving the Quality of Life for Women!” Caldera Medical develops, manufactures and markets best-in-class surgical products for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse Polyps and Fibroids.
Caldera Medical forms close relationships with surgeons and continues to build the company around a principle of customer intimacy. In partnership with its surgeon customers, Caldera Medical has the largest humanitarian program of any women’s health company. It is committed to treating one million women in underserved populations around the world by the year 2027.
About Cynisca Cycling
Cynisca Cycling is a UCI-registered Women’s Continental Team (CYN-USA), dedicated to providing inspiration and support for women to reach the highest levels in cycling - both on and off the bike. The team provides professional support and guidance around a select racing program at the top European and U.S. events.
Launched in 2022 in partnership with USA Cycling, the team began racing in 2023 with an international roster now featuring twelve select North American riders who hold three national titles and a Pan American championship title. Other countries represented include France, Ireland, and Canada. Cynisca is committed to fair pay for female athletes and to providing employment opportunities for women.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627021263/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse and Hungary Establish Landmark Nuclear Fuel Partnership8.11.2025 15:00:00 CET | Press release
First Contract Signed with MVM Group to Deliver VVER-440 Fuel to Paks Nuclear Power Plant Westinghouse Electric Company and MVM Group signed a contract to ensure diversification of fuel supply in Hungary. This partnership brings to Paks Nuclear Power Plant (NPP) reliable supply with Westinghouse VVER fuel, manufactured in Europe. The Westinghouse VVER-440 fuel reload deliveries will start in 2028, subject to licensing activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107682814/en/ Westinghouse Nuclear Fuel Senior Vice President Aziz Dag, left, and Károly Mátrai, CEO of the MVM Group, signed the Paks VVER-440 contract, Nov. 7, 2025. “Our agreement with Westinghouse is a clear response to today's energy challenges and further strengthens the role of Hungary's leading base power plant in the domestic energy supply. This strategically important step will make the operation of Paks Nuclear Power Plant safer and more f
OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”8.11.2025 07:00:00 CET | Press release
OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since April 2024, OMRON has been implementing a Structural Reform Program “NEXT 2025” aimed at rebuilding our foundation for profitability and growth. With the completion of this Program in September 2025, we have shifted into a growth phase and formulated a new Roadmap looking ahead to 2030. This Roadmap identifies Business Portfolio Restructuring as a core strategy. We have defined Thirteen Focus Businesses to drive the Group’s future growth. By accelerating our selection and concentration efforts, we aim to build a “distinctive” business portfolio that maximizes overall Group growth. Furthermore, to maximize the growth potential of our Focus Busines
26th UN Tourism General Assembly kicks off in Riyadh7.11.2025 22:13:00 CET | Press release
UN Tourism marks 50 years of global cooperation as leaders from across the industry gather to shape the future of tourism. His Excellency Ahmed Al Khateeb, Minister of Tourism – “The Kingdom will play an integral part in ensuring one of the world’s most powerful generators of jobs and GDP grows in harmony with the Sustainable Development Goals.” UN Tourism Secretary-General ZurabPololikashvili – “The UN Tourism General Assembly brings together tourism leaders from across the world to set the agenda and build a more innovative and inclusive sector. From Riyadh, we will set the agenda for tourism for the years ahead.” The 26th session of the UN Tourism General Assembly opened today in Riyadh, marking a historic first for the Gulf Cooperation Council (GCC) region and the largest Assembly since UN Tourism was founded 50 years ago. Around 160 delegations from member states including ministers, senior officials, and leaders from across industry and civil society are coming together to celebr
Xsolla Partners With Deloitte Turkiye and Lorien Accelerator as Category Sponsor for Gaming Awards at Fast 50 Türkiye 2025 Program7.11.2025 19:11:00 CET | Press release
Celebrating Turkey’s Gaming Industry with High-Impact Sponsorship and Industry Panel Xsolla, a leading global video game commerce company that helps developers launch, grow, and monetize their games, is proud to announce its sponsorship of the Gaming Awards segment at the Deloitte Technology Fast 50 Türkiye 2025 Program, organized in collaboration with Lorien Accelerator. The event will take place on December 10, 2025, and will recognize Turkey’s top high-growth companies across various industries, with a special focus on the dynamic gaming sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251107671030/en/ Graphic: Xsolla As the Gaming Awards category sponsor, Xsolla will receive significant brand exposure through prominent logo placements across all event materials, including digital platforms, official event signage, and other promotional materials. In addition to this visibility, Xsolla’s participation includes an ex
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy7.11.2025 17:00:00 CET | Press release
− Phase 1b, Open-Label Study Follow Up Shows Stable Kidney Function (eGFR) in Patients Treated with Investigational Mezagitamab Through Week 96 – 18 Months After Last Dose1− Rapid Reductions in Proteinuria and Serum Gd-IgA1 Levels Were Sustained Through Week 961− No Serious Adverse Events or Opportunistic Infections Were Observed Through Week 961− Takeda Initiated Pivotal Phase 3 Clinical Trials Evaluating Mezagitamab in Primary IgA Nephropathy and Immune Thrombocytopenia with Patient Enrollment Ongoing Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
